- Global Pharma News & Resources

B-cell Maturation Antigen (BCMA) Targeted Therapies Market Analysis, Applications, Trends 2020 | Growth Opportunities, Current and Projected Market Size, Recent Industry Developments and forecast 2025

The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody-drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA) targeted therapies market worldwide. Increasing recurrence of multiple myeloma has been a major obstacle. According to the National Cancer Institute, in 2016, around 75,000 patients globally were recorded to be suffering from relapsed or refractory multiple myeloma, with a relative survival rate of 5 years. According to American Cancer Society, as of 2017, around 30,280 multiple myeloma cases are estimated to be diagnosed, out of which around 12,590 deaths are estimated to occur. Multiple myeloma (MM) is the second most common hematological malignancy in the U.S. and European countries.

Request a sample copy of this report@

According to American Cancer Society, in the U.S. the lifetime risk of contracting multiple myeloma is 1 in 143 (0.7%). B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface protein has emerged as a very selective antigen to be targeted for the treatment of multiple myeloma. B-cell maturation antigen possess co-immunoprecipitation property with a master transcription factor (IRF-4) are mediated for myeloma cell survival. This suggests the potential effect of BCMA in oncogenesis, making it a choice of preference for multiple myeloma treatment. Thus, rise in number of multiple myeloma cases and development of novel BCMA therapy for the treatment of multiple myeloma provides lucrative opportunities for the market players. Adoption of BCMA targeted therapies is expected increase, as patients undergoing chemotherapy and radiation therapy are prone to recurrence of cancer.

Tailored Information as per niche requirement:

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

According to the Cancer Research U.K., as of 2014, myeloma is estimated to be the 18th most common cancer in the U.K., with around 15 new cases reported every day. Myeloma rates are projected to grow by 11% or 12 cases per 100,000 people by 2035. According to the National Center for Biotechnology Information (NCBI), in 2014, multiple myeloma represented 8.2% of all blood cancers in Africa. Market players are majorly investing in research and development of novel multiple myeloma therapies, which include chimeric antigen receptor T cells, antibody-drug conjugate, and bispecific antibodies. Preclinical and clinical trial results on these therapies have demonstrated potential benefits. Key player in the market such as Glaxosmithkline Plc. is developing an antibody drug conjugate for the treatment of relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA, whereas Bluebird Bio, Inc. is actively developing an anti-BCMA CAR-T cell drug product to treat relapsed and/or refractory multiple myeloma. Boehringer Ingelheim GmbH is performing clinical trials for relapsed and/or refractory multiple myeloma patients using bispecific antibody.

Browse through 130 Pages and an in-depth TOC on ‘B-cell Maturation Antigen (BCMA) Targeted Therapies, by Product Type (Antibody Drug Conjugates, CAR-T Cells, and Bispecific Antibodies), By Indication (Acute Lymphoblastic Leukemia and Multiple Myeloma), and by Region

To know the latest trends and insights prevalent in the B-cell maturation antigen (BCMA) targeted therapies market press release, click the link below:

Key Takeaways of the Market:

  • According to the American Society of Clinical Oncology (ASCO), in 2016, multiple myeloma was the second most common blood cancer, after non-Hodgkin lymphoma, accounting for 1% of all kinds of malignancies globally, with 70 years being the median age of diagnosis
  • As there are no treatment option available for patients with recurrent cancer, development of therapy to treat relapsed and/or refractory multiple myeloma is expected to provide market players with lucrative opportunities
  • Some of the major players involved in the development of B-cell maturation antigen (BCMA) targeted therapies market are Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.
About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 11-Feb-2021